Cancer Research Cell Death Mechanisms and Cancer Therapy Protein Translation and Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Machiels, J.-P. H.
Right arrow Articles by Jaffee, E. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Machiels, J.-P. H.
Right arrow Articles by Jaffee, E. M.
[Cancer Research 61, 3689-3697, May 1, 2001]
© 2001 American Association for Cancer Research

Immunology

Cyclophosphamide, Doxorubicin, and Paclitaxel Enhance the Antitumor Immune Response of Granulocyte/Macrophage-Colony Stimulating Factor-secreting Whole-Cell Vaccines in HER-2/neu Tolerized Mice1

Jean-Pascal H. Machiels, R. Todd Reilly, Leisha A. Emens, Anne M. Ercolini, Rachel Y. Lei, Diane Weintraub, Francesca I. Okoye and Elizabeth M. Jaffee2

The Johns Hopkins University School of Medicine, Department of Oncology, Graduate Program in Immunology, Baltimore, Maryland 21231

Tumor-specific immune tolerance limits the effectiveness of cancer vaccines. In addition, tumor vaccines alone have a limited potential for the treatment of measurable tumor burdens. This highlights the importance of identifying more potent cancer vaccine strategies for clinical testing. We tested immune-modulating doses of chemotherapy in combination with a granulocyte/macrophage-colony stimulating factor (GM-CSF)-secreting, HER-2/neu (neu)-expressing whole-cell vaccine as a means to treat existing mammary tumors in antigen-specific tolerized neu transgenic mice. Earlier studies have shown that neu transgenic mice exhibit immune tolerance to the neu-expressing tumors similar to what is observed in patients with cancer. We found that cyclophosphamide, paclitaxel, and doxorubicin, when given in a defined sequence with a GM-CSF-secreting, neu-expressing whole-cell vaccine, enhanced the vaccine‘s potential to delay tumor growth in neu transgenic mice. In addition, we showed that these drugs mediate their effects by enhancing the efficacy of the vaccine rather than via a direct cytolytic effect on cancer cells. Furthermore, paclitaxel and cyclophosphamide appear to amplify the T helper 1 neu-specific T-cell response. These findings suggest that the combined treatment with immune-modulating doses of chemotherapy and the GM-CSF-secreting neu vaccine can overcome immune tolerance and induce an antigen-specific antitumor immune response. These data provide the immunological rationale for testing immune-modulating doses of chemotherapy in combination with tumor vaccines in patients with cancer.




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
K. A. Smith, B. L. Meisenburg, V. L. Tam, R. R. Pagarigan, R. Wong, D. K. Joea, L. Lantzy, M. A. Carrillo, T. M. Gross, U. M. Malyankar, et al.
Lymph Node-Targeted Immunotherapy Mediates Potent Immunity Resulting in Regression of Isolated or Metastatic Human Papillomavirus-Transformed Tumors
Clin. Cancer Res., October 1, 2009; 15(19): 6167 - 6176.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. G. Drake
Immunotherapy for Prostate Cancer: Walk, Don't Run
J. Clin. Oncol., September 1, 2009; 27(25): 4035 - 4037.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
H. Tanaka, H. Matsushima, A. Nishibu, B. E. Clausen, and A. Takashima
Dual Therapeutic Efficacy of Vinblastine as a Unique Chemotherapeutic Agent Capable of Inducing Dendritic Cell Maturation
Cancer Res., September 1, 2009; 69(17): 6987 - 6994.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Wada, K. Yoshimura, E. L. Hipkiss, T. J. Harris, H.-R. Yen, M. V. Goldberg, J. F. Grosso, D. Getnet, A. M. Demarzo, G. J. Netto, et al.
Cyclophosphamide Augments Antitumor Immunity: Studies in an Autochthonous Prostate Cancer Model
Cancer Res., May 15, 2009; 69(10): 4309 - 4318.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
D. Hirschhorn-Cymerman, G. A. Rizzuto, T. Merghoub, A. D. Cohen, F. Avogadri, A. M. Lesokhin, A. D. Weinberg, J. D. Wolchok, and A. N. Houghton
OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis
J. Exp. Med., May 11, 2009; 206(5): 1103 - 1116.
[Abstract] [Full Text] [PDF]

Home page
 Arch Otolaryngol Head Neck SurgHome page
D. W. Lee, M. E. Anderson, S. Wu, and J. H. Lee
Development of an Adenoviral Vaccine Against E6 and E7 Oncoproteins to Prevent Growth of Human Papillomavirus-Positive Cancer
Arch Otolaryngol Head Neck Surg, December 1, 2008; 134(12): 1316 - 1323.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. Song, K. Shahverdi, D. L. Huso, Y. Wang, J. J. Fox, R. F. Hobbs, B. Gimi, K. L. Gabrielson, M. G. Pomper, B. M. Tsui, et al.
An Immunotolerant HER-2/neu Transgenic Mouse Model of Metastatic Breast Cancer
Clin. Cancer Res., October 1, 2008; 14(19): 6116 - 6124.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. T. Garnett, J. Schlom, and J. W. Hodge
Combination of Docetaxel and Recombinant Vaccine Enhances T-Cell Responses and Antitumor Activity: Effects of Docetaxel on Immune Enhancement
Clin. Cancer Res., June 1, 2008; 14(11): 3536 - 3544.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. L. Gulley, P. M. Arlen, K.-Y. Tsang, J. Yokokawa, C. Palena, D. J. Poole, C. Remondo, V. Cereda, J. L. Jones, M. P. Pazdur, et al.
Pilot Study of Vaccination with Recombinant CEA-MUC-1-TRICOM Poxviral-Based Vaccines in Patients with Metastatic Carcinoma
Clin. Cancer Res., May 15, 2008; 14(10): 3060 - 3069.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C.-W. Tseng, C.-F. Hung, R. D. Alvarez, C. Trimble, W. K. Huh, D. Kim, C.-M. Chuang, C.-T. Lin, Y.-C. Tsai, L. He, et al.
Pretreatment with Cisplatin Enhances E7-Specific CD8+ T-Cell-Mediated Antitumor Immunity Induced by DNA Vaccination
Clin. Cancer Res., May 15, 2008; 14(10): 3185 - 3192.
[Abstract] [Full Text] [PDF]

Home page
 Exp. Biol. Med.Home page
J. Schlom, J. L. Gulley, and P. M. Arlen
Paradigm Shifts in Cancer Vaccine Therapy
Experimental Biology and Medicine, May 1, 2008; 233(5): 522 - 534.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Ladoire, L. Arnould, L. Apetoh, B. Coudert, F. Martin, B. Chauffert, P. Fumoleau, and F. Ghiringhelli
Pathologic Complete Response to Neoadjuvant Chemotherapy of Breast Carcinoma Is Associated with the Disappearance of Tumor-Infiltrating Foxp3+ Regulatory T Cells
Clin. Cancer Res., April 15, 2008; 14(8): 2413 - 2420.
[Abstract] [Full Text] [PDF]

Home page
 Am Soc Clin Oncol Ed BookHome page
J. Schlom, P. M. Arlen, and J. L. Gulley
Immunotherapies with Other Therapeutic Modalities: New Paradigms for Clinical Trial Design
ASCO Educational Book, January 1, 2008; 2008(1): 101 - 106.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P. Berraondo, C. Nouze, X. Preville, D. Ladant, and C. Leclerc
Eradication of Large Tumors in Mice by a Tritherapy Targeting the Innate, Adaptive, and Regulatory Components of the Immune System
Cancer Res., September 15, 2007; 67(18): 8847 - 8855.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
E. M. Wall, K. Milne, M. L. Martin, P. H. Watson, P. Theiss, and B. H. Nelson
Spontaneous Mammary Tumors Differ Widely in Their Inherent Sensitivity to Adoptively Transferred T Cells
Cancer Res., July 1, 2007; 67(13): 6442 - 6450.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Schlom, P. M. Arlen, and J. L. Gulley
Cancer Vaccines: Moving Beyond Current Paradigms
Clin. Cancer Res., July 1, 2007; 13(13): 3776 - 3782.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. A. Manning, J. G.M. Ullman, J. M. Leatherman, J. M. Asquith, T. R. Hansen, T. D. Armstrong, D. J. Hicklin, E. M. Jaffee, and L. A. Emens
A Vascular Endothelial Growth Factor Receptor-2 Inhibitor Enhances Antitumor Immunity through an Immune-Based Mechanism
Clin. Cancer Res., July 1, 2007; 13(13): 3951 - 3959.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
G. C. Prendergast and E. M. Jaffee
Cancer Immunologists and Cancer Biologists: Why We Didn't Talk Then but Need to Now
Cancer Res., April 15, 2007; 67(8): 3500 - 3504.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P. Nava-Parada, G. Forni, K. L. Knutson, L. R. Pease, and E. Celis
Peptide Vaccine Given with a Toll-Like Receptor Agonist Is Effective for the Treatment and Prevention of Spontaneous Breast Tumors
Cancer Res., February 1, 2007; 67(3): 1326 - 1334.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. Bracci, F. Moschella, P. Sestili, V. La Sorsa, M. Valentini, I. Canini, S. Baccarini, S. Maccari, C. Ramoni, F. Belardelli, et al.
Cyclophosphamide Enhances the Antitumor Efficacy of Adoptively Transferred Immune Cells through the Induction of Cytokine Expression, B-Cell and T-Cell Homeostatic Proliferation, and Specific Tumor Infiltration
Clin. Cancer Res., January 15, 2007; 13(2): 644 - 653.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Vieweg, Z. Su, P. Dahm, and S. Kusmartsev
Reversal of Tumor-Mediated Immunosuppression
Clin. Cancer Res., January 15, 2007; 13(2): 727s - 732s.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. Brode, T. Raine, P. Zaccone, and A. Cooke
Cyclophosphamide-Induced Type-1 Diabetes in the NOD Mouse Is Associated with a Reduction of CD4+CD25+Foxp3+ Regulatory T Cells
J. Immunol., November 15, 2006; 177(10): 6603 - 6612.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
C. P. Tarassoff, P. M. Arlen, and J. L. Gulley
Therapeutic vaccines for prostate cancer.
Oncologist, May 1, 2006; 11(5): 451 - 462.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J. Taieb, N. Chaput, N. Schartz, S. Roux, S. Novault, C. Menard, F. Ghiringhelli, M. Terme, A. F. Carpentier, G. Darrasse-Jese, et al.
Chemoimmunotherapy of tumors: cyclophosphamide synergizes with exosome based vaccines.
J. Immunol., March 1, 2006; 176(5): 2722 - 2729.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. M. Arlen, J. L. Gulley, C. Parker, L. Skarupa, M. Pazdur, D. Panicali, P. Beetham, K. Y. Tsang, D. W. Grosenbach, J. Feldman, et al.
A Randomized Phase II Study of Concurrent Docetaxel Plus Vaccine Versus Vaccine Alone in Metastatic Androgen-Independent Prostate Cancer
Clin. Cancer Res., February 15, 2006; 12(4): 1260 - 1269.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. Butts, N. Murray, A. Maksymiuk, G. Goss, E. Marshall, D. Soulieres, Y. Cormier, P. Ellis, A. Price, R. Sawhney, et al.
Randomized Phase IIB Trial of BLP25 Liposome Vaccine in Stage IIIB and IV Non-Small-Cell Lung Cancer
J. Clin. Oncol., September 20, 2005; 23(27): 6674 - 6681.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. A. Emens and E. M. Jaffee
Leveraging the Activity of Tumor Vaccines with Cytotoxic Chemotherapy
Cancer Res., September 15, 2005; 65(18): 8059 - 8064.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. J. Muller and G. C. Prendergast
Marrying Immunotherapy with Chemotherapy: Why Say IDO?
Cancer Res., September 15, 2005; 65(18): 8065 - 8068.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
R. Singh, M. E. Dominiecki, E. M. Jaffee, and Y. Paterson
Fusion to Listeriolysin O and Delivery by Listeria monocytogenes Enhances the Immunogenicity of HER-2/neu and Reveals Subdominant Epitopes in the FVB/N Mouse
J. Immunol., September 15, 2005; 175(6): 3663 - 3673.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
A. M. Ercolini, B. H. Ladle, E. A. Manning, L. W. Pfannenstiel, T. D. Armstrong, J.-P. H. Machiels, J. G. Bieler, L. A. Emens, R. T. Reilly, and E. M. Jaffee
Recruitment of latent pools of high-avidity CD8+ T cells to the antitumor immune response
J. Exp. Med., May 16, 2005; 201(10): 1591 - 1602.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. E. C. Lutsiak, R. T. Semnani, R. De Pascalis, S. V. S. Kashmiri, J. Schlom, and H. Sabzevari
Inhibition of CD4+25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide
Blood, April 1, 2005; 105(7): 2862 - 2868.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. Casati, V. S. Zimmermann, F. Benigni, M. T. S. Bertilaccio, M. Bellone, and A. Mondino
The Immunogenicity of Dendritic Cell-Based Vaccines Is Not Hampered by Doxorubicin and Melphalan Administration
J. Immunol., March 15, 2005; 174(6): 3317 - 3325.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
P. Yu, Y. Lee, W. Liu, T. Krausz, A. Chong, H. Schreiber, and Y.-X. Fu
Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors
J. Exp. Med., March 7, 2005; 201(5): 779 - 791.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
L A Emens, R T Reilly, and E M Jaffee
Breast cancer vaccines: maximizing cancer treatment by tapping into host immunity
Endocr. Relat. Cancer, March 1, 2005; 12(1): 1 - 17.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. T. Garnett, C. Palena, M. Chakarborty, K.-Y. Tsang, J. Schlom, and J. W. Hodge
Sublethal Irradiation of Human Tumor Cells Modulates Phenotype Resulting in Enhanced Killing by Cytotoxic T Lymphocytes
Cancer Res., November 1, 2004; 64(21): 7985 - 7994.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. R. Bishop, D. H. Fowler, D. Marchigiani, K. Castro, C. Kasten-Sportes, S. M. Steinberg, J. C. Gea-Banacloche, R. Dean, C. K. Chow, C. Carter, et al.
Allogeneic Lymphocytes Induce Tumor Regression of Advanced Metastatic Breast Cancer
J. Clin. Oncol., October 1, 2004; 22(19): 3886 - 3892.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
D. E. Spaner
Amplifying cancer vaccine responses by modifying pathogenic gene programs in tumor cells
J. Leukoc. Biol., August 1, 2004; 76(2): 338 - 351.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. A. Mihalyo, A. D. H. Doody, J. P. McAleer, E. C. Nowak, M. Long, Y. Yang, and A. J. Adler
In Vivo Cyclophosphamide and IL-2 Treatment Impedes Self-Antigen-Induced Effector CD4 Cell Tolerization: Implications for Adoptive Immunotherapy
J. Immunol., May 1, 2004; 172(9): 5338 - 5345.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
I. F. Hermans, T. W. Chong, M. J. Palmowski, A. L. Harris, and V. Cerundolo
Synergistic Effect of Metronomic Dosing of Cyclophosphamide Combined with Specific Antitumor Immunotherapy in a Murine Melanoma Model
Cancer Res., December 1, 2003; 63(23): 8408 - 8413.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. E. Wolpoe, E. R. Lutz, A. M. Ercolini, S. Murata, S. E. Ivie, E. S. Garrett, L. A. Emens, E. M. Jaffee, and R. T. Reilly
HER-2/neu-Specific Monoclonal Antibodies Collaborate with HER-2/neu-Targeted Granulocyte Macrophage Colony-Stimulating Factor Secreting Whole Cell Vaccination to Augment CD8+ T Cell Effector Function and Tumor-Free Survival in Her-2/neu-Transgenic Mice
J. Immunol., August 15, 2003; 171(4): 2161 - 2169.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. M. Ercolini, J.-P. H. Machiels, Y. C. Chen, J. E. Slansky, M. Giedlen, R. T. Reilly, and E. M. Jaffee
Identification and Characterization of the Immunodominant Rat HER-2/neu MHC Class I Epitope Presented by Spontaneous Mammary Tumors from HER-2/neu-Transgenic Mice
J. Immunol., April 15, 2003; 170(8): 4273 - 4280.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Y. Miyagi, N. Imai, T. Sasatomi, A. Yamada, T. Mine, K. Katagiri, M. Nakagawa, A. Muto, S. Okouchi, H. Isomoto, et al.
Induction of Cellular Immune Responses to Tumor Cells and Peptides in Colorectal Cancer Patients by Vaccination with SART3 Peptides
Clin. Cancer Res., December 1, 2001; 7(12): 3950 - 3962.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2001 by the American Association for Cancer Research.